Investor News / RNS

The Company announces that Dr Jim Millen, Chief Executive Officer of Physiomics, has transferred, for no consideration, 242,287 ordinary shares of 0.4p each in the Company (“Ordinary Shares”) from a brokerage account with James Brearley & Sons Limited to an account with Interactive Investors.  The Ordinary Shares remain beneficially owned by Dr Millen. Dr Millen’s holding in the Company therefore remains 1,384,393 Ordinary Shares, representing approximately...

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded two further contracts by existing client Bicycle Therapeutics (“Bicycle”) that it expects to be completed over the next six months.  These projects relate to two of Bicycle’s lead clinical assets and build on earlier work...

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a further contract by existing client Merck KGaA (“Merck”) that it expects to be completed over the next two to three months.  This contract follows on from and is additional to the initial tranche of...

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a first contract by new client Numab Therapeutics (“Numab”). Numab is an exciting young biopharmaceutical company based in Zurich, Switzerland which is developing multi-specific biotherapeutics for chronic inflammation and cancer.  Physiomics has recent significant experience...

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, today announces that its total income for the financial year ending 30 June 2021 is likely to be in the range of £700k-£800k and its loss after tax in the range of £170-200k. This is below market expectations and due to both COVID related...

Physiomics to present on Personalized Medicine and Virtual Tumour at AACR 2021 Annual Meeting Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it is participating in the American Academy of Cancer Research (“AACR”) Annual Meeting 2021, being held as a virtual event. The Company will be presenting two...

The Company announces that Dr Jim Millen, Chief Executive Officer of Physiomics, has been notified that a brokerage account with Reyker Securities plc (“Reyker”) in which he held an interest of 244,641 ordinary shares of 0.4p each in the Company (“Ordinary Shares”), has been closed and transferred to a brokerage account with James Brearley & Sons Limited, for no consideration (the “Transfer”). Click here to read...

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, yesterday made a presentation regarding its interim results for the 6 months ended 31 December 2020, using the Investor Meet Company platform. The slide deck used in the presentation can be accessed on the Company’s website using the following link: https://www.physiomics.co.uk/wp-content/uploads/2021/03/Physiomics-Update-11-Mar-2021.pdf A recording of the presentation,...

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that the Company’s CEO, Jim Millen, will provide a live presentation relating to its interim results for the six-month period ended 31 December 2020, via the Investor Meet Company platform, on 11 Mar 2021, at 11:00am GMT. The presentation is...

The Company considers that the award of options linked to the Company’s performance is critical to the incentivisation of its directors and employees and to ensure that there is alignment between management and shareholders. Click here to read in full....

Physiomics today announces its financial results for the six months ended 31 December 2020. Click here to read in full....

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has entered into a new agreement with ValiRx plc (AIM:VAL), a clinical stage drug development company.  The new agreement supersedes the agreement between Physiomics and ValiRx which was announced on 13 September 2011. Under the terms of the...

TR-1: Standard form for notification of major holdings Please click here to read in full....

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, today announces it has entered into a partnership with Tabula Rasa HealthCare® (“TRHC”) (NASDAQ:TRHC), a healthcare technology company advancing the field of medication safety. Through this initiative, Physiomics’ personalised docetaxel model will be integrated into TRHC’s market-leading precision dosing solution, DoseMeRx®. Both parties...

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that its existing client, Merck KGaA (“Merck”), has today committed to an initial tranche of projects for 2021 with an aggregate value of £270,000. These projects are expected to be completed during the first six to eight months of...

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that its National Institute for Health Research (“NIHR”) Invention for Innovation (“i4i”) programme funded observational clinical study (designated “PARTNER”), has this week received both ethics committee and Health Research Authority (HRA) approval and it is now expected that the...

Physiomics plc (“Physiomics” “the Company”) Result of AGM Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that all resolutions put to shareholders at the Company's Annual General Meeting, held earlier today at the Company’s offices in Oxford, were duly passed.   Enquiries: Physiomics plc Dr Jim Millen, CEO +44 (0)1865 784 980 Strand Hanson Ltd...

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has today posted to shareholders its Annual Report and Accounts for the financial year ended 30 June 2020, together with its Notice of Annual General Meeting (“AGM”). As announced on 30 September 2020, the Company’s AGM will be...

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded further contracts of undisclosed value for projects with existing clients Bicycle Therapeutics plc (“Bicycle”) and Merck KGaA (“Merck”). The project with Bicycle is the eighth signed with this high-profile UK biotech company, spanning four different...

Physiomics plc (“Physiomics” or “the Company”)  Presentation and Q&A on Company’s Final Results for the year ended 30 June 2020 Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, yesterday made a presentation regarding its final results for the year ended 30 June 2020, using the Investor Meet Company platform.  The slide deck used in...

Highlights  Financial Highlights Total income (revenue and grant income) increased 7% to £841,649 (2019: £783,101), the highest in the Company’s history The operating loss decreased 33% to £134,385 (2019: £201,219) The loss after taxation decreased 38% to £64,424 (2019: £104,040) Placing and subscription in May 2020 raised £828,750 (gross) through the issue of 23,678,571 new ordinary shares at an issue price of 3.5 pence per share ...

The Company is pleased to announce that it will release its results for the year ended 30 June 2020 at 7.00 a.m. on Wednesday 30 September 2020. In addition, management is pleased to confirm that they will provide a live presentation relating to the Company’s results via the Investor Meet Company (“IMC”) platform on Monday 5 October 2020, at 11.00 a.m. The online presentation is open...

TR-1: Standard form for notification of major holdings Please click here to read in full....

The Company announces that it received notice today that Dr Jim Millen sold 597,332 ordinary shares in the Company at 6.45p per share to cover the cost of his exercise of options announced on 5 August 2020. Click here to read in full....

Physiomics plc, a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, announces that, further to its announcement earlier today and following the receipt of an additional notice of exercise of employee options, 90,000 ordinary shares of 0.4p each in the Company (“Ordinary Shares”) (the “Options Shares”) will be issued to the an employee at an exercise price...

Physiomics plc, a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, announces that following the receipt of notices of exercise of employee options, 1,655,813 ordinary shares of 0.4p each in the Company (“Ordinary Shares”) (the “Options Shares”) have now been issued to the following employees at the following exercise prices: Click here to read in full...

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to confirm that, based on its unaudited management accounts for the year ended 30 June 2020, the Company is trading in line with analyst expectations. Trading for the current financial year has started well with a further contract with Bicycle Therapeutics (announced on...

Physiomics awarded contract by Astellas Pharma Inc. Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that, further to its announcements of 27 May, 30 June and 22 July 2020, it has been awarded a contract by a new client, Astellas Pharma Inc. (TSE:...

Physiomics reports that Dr Jim Millen, CEO, has transferred 85,715 ordinary shares of 0.4p each in the capital of the Company (“Ordinary Shares”), acquired during the recently placing, announced on 27 May 2020, to his account with The Share Centre for nil consideration, effective 2 July 2020.  Click here to read in full.    ...

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a further contract of undisclosed value by existing client Bicycle Therapeutics plc (Nasdaq: BCYC) (“Bicycle”).  The project involves advanced translational pharmacokinetic modelling of one of Bicycle’s pipeline assets and...

Physiomics to present on dual immuno-therapy at AACR 2020 Virtual Meeting II Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it is participating in the American Academy of Cancer Research (“AACR”) Annual Meeting 2020, being held as a virtual event. The Company will be presenting on a new version...

TR-1: Standard form for notification of major holdings Please click here to read in full....

Physiomics completes £0.83m (gross) fundraise to fund growth opportunities Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has completed a placing and subscription, conditional on Admission, to raise approximately £828,750 (gross) from the issue of 23,678,571 new ordinary shares of 0.4p...

TR-1: Standard form for notification of major holdings Please click here to read in full....

Physiomics attends BioTrinity 2020 Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it is participating in the BioTrinity 2020 conference which is being held digitally this week.  In lieu of face to face meetings, the Company has made a pre-recorded presentation...

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, would like to note that its only official twitter account is @Physiomics. It has come to the Company’s attention that a twitter account with a similar name, @Physiomics1, which was set up in February this year, has been tweeting...

TR-1: Standard form for notification of major holdings Please click here to read in full....

Physiomics awarded further contract by Bicycle Therapeutics Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a further contract of undisclosed value by its existing client, Bicycle Therapeutics (“Bicycle”) (the “Project”). The Project is an extension of the work the...

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, would like to update its shareholders in light of the rapidly evolving COVID-19 outbreak. The Company’s first concern is of course for the well-being of its employees and to this end, the Company is pleased to confirm that many...

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a “Connect” award by the National Institute for Health Research (“NIHR”) Invention for Innovation (“i4i”) programme in respect of the Company’s continued development of its tool for use in...

Physiomics awarded further contract by Merck Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a further contract of undisclosed value by its existing client Merck KGaA (“Merck”). This contract is an extension of one of the projects awarded and...

Physiomics today announces its financial results for the six months ended 31 December 2019. Click here to read more...

Physiomics awarded two further contracts by Bicycle Therapeutics Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded two further contracts of undisclosed value with its existing client Bicycle Therapeutics (“Bicycle”), building on the two projects announced in 2019. Last year...

TR-1: Standard form for notification of major holdings Please click here to read in full....

Physiomics signs further project agreement with CellCentric Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens for the biopharma industry, is delighted to announce that it has been awarded a further contract by existing UK based biotech client, CellCentric.  The value of the contract is not disclosed but is expected to complete in the first half of...

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens for the biopharma industry, is pleased to announce that, following a successful collaboration this year its client Merck KGaA ("Merck") has today committed to an initial tranche of projects for 2020 with an aggregate value of £250,000.  These projects are expected to be...

The Company held its Annual General Meeting at its offices in Oxford on 19 November 2019 and is pleased to announce that all resolutions put to shareholders were duly passed.   Enquiries: Physiomics plc Dr Jim Millen, CEO +44 (0)1865 784 980 Strand Hanson Ltd (NOMAD) Richard Tulloch & James Dance +44 (0)20 7409 3494 Hybridan LLP (Broker) Claire Louise Noyce +44 (0)20 3764 2341   Notes to Editor About Physiomics Physiomics plc (AIM: PYC) is a provider of technology-based...

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens, is pleased to announce that it has today posted to shareholders its Annual Report and Accounts for the financial year ended 30 June 2019 together with its Notice of Annual General Meeting (“AGM”). As previously announced on the 30 September 2019, the Company’s AGM will be held at 10.00...

Highlights Financial: Total income (revenue and grant income) increased 53% to £783,101 (2018: £512,899) The operating loss decreased 23% to £201,219 (2018 £260,391) The loss after taxation decreased 43% to £104,040 (2018: £183,341) At 30 June 2019, the surplus of shareholders’ funds was £607,914 (30 June 2018: £690,026) Cash and cash equivalents at 30 June 2019 of £405,366 (30 June 2018: £571,869) Click here to read in...

The Company announces that it received notice today that the following Directors acquired the following number of ordinary shares in the Company at the following prices per share. Click here to read in full...

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to confirm that, based on its unaudited management accounts for the year ended 30 June 2019, the Company is trading in line with analyst expectations. The Company expects to publish its final audited results for the year ending 30 June 2019 during the...

TR-1: Standard form for notification of major holdings Click here to read in full....

Physiomics signs agreement with Bicycle Therapeutics and Cancer Research UK Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it has signed an agreement to work with Bicycle Therapeutics and Cancer Research UK.  The project is expected to be completed during this calendar year and will focus on the...

TR-1: Standard form for notification of major holdings Click here to read in full....

Physiomics signs agreement with Bicycle Therapeutics to support immune-oncology program Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it has been awarded a contract by Bicycle Therapeutics plc (Nasdaq: BCYC) (“Bicycle”).  The project will focus on the mathematical computer modelling of interactions between tumour and Bicycle® compounds in...

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it has appointed Strand Hanson Limited as its Nominated and Financial Adviser, with immediate effect. Hybridan LLP will continue to act as the Company’s sole broker.   Enquiries:   Physiomics plc Dr Jim Millen, CEO +44 (0)1865 784 980   Strand Hanson Ltd (NOMAD) Richard Tulloch & James Dance +44...

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to confirm that is has successfully completed the Innovate UK grant project announced in March 2018.  The project was formally signed off by Innovate UK following a final project meeting in April 2019. The Company can confirm that, in line with expectations,...

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, yesterday participated in the “SME Dragon’s Den” event jointly organised by the National Institute for Health Research (“NIHR”) Biomedical Research Centre at The Royal Marsden NHS Foundation Trust, the Institute of Cancer Research and DigitalHealth London Accelerator. Dr Claire Villette and Dr Jim Millen presented...

Physiomics presents at the BioTrinity 2019 meeting in London Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it presented today at the BioTrinity 2019 annual conference in London.  The presentation is available on the “resources” section of our website here https://www.physiomics.co.uk/wp-content/uploads/2019/04/Physiomics-Presentation-Biotrinity-2019.pdf. The Company also took the opportunity to meet...

The Company considers that the award of options linked to company performance are critical to the incentivisation of its senior employees and to ensure that there is alignment between management and shareholders.  To this end, the Company today confirms that it has agreed to issue share options to its directors, as detailed in this announcement.  Each option forming part of this award is exercisable at...

  AIM Rule 26 Website Change  Physiomics updates its branding, website and URL to improve customer experience Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce it has undertaken an exercise to “modernise and simplify” its online image in advance of its attendance at the American Association for Cancer Research Annual Meeting...

Physiomics to present on personalised medicine and Virtual Tumour™ developments at AACR 2019 meeting Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it is participating in the American Association of Cancer Research (“AACR”) Annual Meeting 2019, taking place in Atlanta, Georgia, 29th March to 3rd April.  The company...

Oxford, UK, 21 February 2019: The Board of Physiomics Plc, a provider of technology- based solutions to predict the effects of cancer treatment regimens for the biopharma industry (AIM: PYC), today announces its financial results for the six months ended 31 December 2018. Click here to read in full. ...

Physiomics plc (AIM: PYC), is pleased to announce that it will be attending the Biotech Showcase partnering conference in San Francisco from 7-9 January 2019 during the JP Morgan Healthcare Conference week. During this week, many of the world’s most successful biotech and pharmaceutical companies are present in San Francisco to meet with prospective clients and partners. Over three thousand attendees are expected to participate...

Physiomics plc (AIM: PYC), is pleased to announce that it has entered into a strategic collaboration with the Medicines Discovery Catapult. Physiomics will be part of the “Virtual R&D” network of advisors and available to provide advice to the many small biotechnology companies supported by Medicines Discovery Catapult. Click here to read in full.  ...

Physiomics plc (Oxford, UK) is pleased to announce that, following a successful collaboration this year and pursuant to the Master Services Agreement signed with Merck, a leading science and technology company, in November 2017, it has agreed with its client a program of work for the next calendar year. Click here to read in full....

The Company held its Annual General Meeting at its offices in Oxford on 20th November 2018 and is pleased to announce that all resolutions put to shareholders were passed. Please click here to read in full....

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has today posted to shareholders its Annual Report for the financial year ended 30th June 2018 and a Circular in relation to its forthcoming Annual General Meeting Please click here to read in full....

Chairman and Chief Executive Officer’s Statement Introduction We are very pleased to report on a year when we generated the highest total income in the Company’s history.  Having secured the agreement with Merck KGaA in November 2017, we were able to turn our attention to our pipeline and, leveraging the publicity generated by the Merck deal we converted two large pharmaceutical clients and a biotech client in...

Physiomics is delighted to announce that it has been awarded a contract by a new European biotech client.  The value of the contract is £55k and it is expected to complete in this calendar year. Click here to read in full....

Physiomics is pleased to announce that Dr Claire Villette has joined its technical team as a Biosimulation scientist. Click here to read in full....

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to confirm that based on its current unaudited accounts at 20th June, it is trading ahead of market expectations for its full financial year ending 30th June 2018. Click here to read in full...

Physiomics is pleased to announce that following feedback from clients and shareholders it has today updated its website at http://www.physiomics-plc.com/.  In its recent placing announcement of the 23 May 2018, the Company stated its intention to improve its marketing approach, and the launch of the new site is a small but important step towards executing this goal.  Features of the upgraded site include: Fresher, cleaner...

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it has completed a placing, conditional only on Admission, to raise £525,000.00 (gross) from the issue of 13,125,000 new ordinary shares of 0.4p each ("Ordinary Shares") at a price of 4.0p per share, through Hybridan LLP (the "Placing"). Application...

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is delighted to announce that it has been awarded a contract by a new UK based biotech client.  The value of the contract is £48k and it is expected to complete in this calendar year. Click here to read in full....

The Company announces that it received notice today that Dr Chassagnole (COO) transferred paper share certificates of 121,522 shares and 265,111 shares to his nominee account ‘Interactive Investor Services Nominees Limited’. Click here to read in full...

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it is participating in the AACR Annual Meeting 2018, taking place at the McCormick Place Convention Center, Chicago, Illinois, on 14-18 April 2018.  Dr Hitesh Mistry will present a poster based on the Company’s recently completed personalised medicine project. Click here to...

The Company considers that the award of options linked to company performance are critical to the incentivisation of its senior employees and to ensure that there is alignment between management and shareholders....

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens, is pleased to announce that is has been awarded a new grant by Innovate UK, the UK’s innovation agency....

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to confirm that is has successfully completed the Innovate UK grant project announced in January 2017. ...

Oxford, UK, 19 February 2018: The Board of Physiomics Plc, a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry (AIM: PYC), today announces its financial results for the six months ended 31 December 2017. Please click here to read in full...

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is delighted to announce that it has been awarded a contract by a further major (global top-10) pharmaceutical client. Click here to read in full...

Physiomics plc is pleased to announce that it has been awarded a contract by a new major pharmaceutical client.  The project, which is expected to be completed during the Company's current financial year involves the use of Physiomics' Virtual Tumour technology in a pre-clinical setting and its value is approximately £35k. Click here to read in full...

TR-1: Standard form for notification of major holdings Click here to read in full...

TR-1: Standard form for notification of major holdings Click here to read in full...

TR-1: Standard form for notification of major holdings Click here to read in full...

TR-1: Standard form for notification of major holdings Click here to read in full....

The Company held its Annual General Meeting at its offices in Oxford on 13th December 2017 Click here to read more...

The Company announces that it received notice today that the following Directors sold the following number of ordinary shares in the Company at the following prices per share: Click here to read more....

Physiomics plc announces today that following the receipt of notice of exercise of employee options, 1,768,815 Ordinary Shares of 0.4p each in the Company (the “Options Shares”) have now been issued to the following employees at the following exercise prices: Please click here to read more....

Following the movement in the Physiomics share price today the Company would like to draw investors’ attention to its RNS of the 28th of November in which the Company announced the signing of a Master Services Agreement (“Agreement”) with Merck KGaA whose minimum value in the first twelve months of the contract is €500,000 (equivalent to around 60% of our net operating expenses for the...

Physiomics plc (AIM: PYC) is pleased to announce that the human Virtual Tumour (“VT”) project with Merck, a leading science and technology company, first announced in March 2015, has now been successfully completed and that it has today entered into a Master Services Agreement (“Agreement”) with Merck. Please click here to read in full...

  Dispatch of Documentation Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has published and posted to shareholders its Annual Report for the financial year ended 30th June 2017 and a circular in relation to its forthcoming Annual General Meeting As already announced on the 16th October 2017, the Company’s Annual General Meeting will be held at 10:00 a.m....

  Chairman's Statement Summary of Results in the year ended 30 June 2017 Total income (revenue and grant income) decreased 9% to £270,465 (2016: £297,120) The operating loss before exceptional costs increased 20% to £489,190 (2016: £408,614) The loss for the year attributable to equity shareholders increased 6% to £400,526 (2016: £378,697) On 30 June 2017, the surplus of shareholders’ funds was £328,254 (2016: £204,153) This year, Physiomics...

Physiomics plc (AIM: PYC) is pleased to announce positive developments relating to its core oncology and simulation business and to provide commentary on potential business collaborations and progress in diversifying into the personalised medicine space. For more information please click here.  ...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has today signed two new contracts with a global pharma company for Virtual Tumour pre-clinical predictions relating to a new oncology target. Please see here for further information...

Oxford, UK, 6th June 2017: Physiomics is pleased to announce that it will attend the Population Approach Group Europe (PAGE) Annual Conference taking place in Budapest, Hungary 7-9 June. PAGE is Europe’s premier conference focused on Quantitative Pharmacology and attracts the top biotech, pharma executives as well as academics working in the field. Physiomics will have a stand at the conference and has arranged a number...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has been contracted for two further extensions to a Virtual Tumour project with a major global pharmaceutical company, first announced on 1st March 2012. Please see here for more information....

Oxford, UK, 24 March 2017: The Board of Physiomics Plc (AIM: PYC), a UK-based systems biology company, today announces its financial results for the six months ended 31 December 2016. Physiomics Plc is a computational systems biology services company whose core technology, Virtual Tumour, predicts the effects of combination chemotherapy in pre-clinical and clinical settings and helps its clients to develop better drugs, faster and...

Physiomics plc (AIM: PYC) is pleased to announce that it is making good progress towards the strategic objectives announced in its most recent full year results (RNS 27th October 2016 and subsequent printed annual report circulated to shareholders). On the 5th December 2016 Physiomics announced an initial payment by Sareum for modelling carried out by the Company in 2010 to support the identification of an optimal...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to confirm that is has been awarded the Innovate UK grant as part of its Biomedical Catalyst 2016 Feasibility Study Competition that was the subject of a provisional announcement on the 22nd November 2016. As previously disclosed, the proposed project is titled “Decision Support Systems For Stratified Cancer Treatment”. In line with the...

The Company confirms that it has agreed to issue share options to its directors, as follows: 1. 879,521 share options over ordinary shares in the Company ("Share Options") have been granted to Christophe Chassagnole under the Enterprise Management Initiative Scheme ("EMI"). The options are exercisable at a price of 2.5p each (being the price of the placing carried out by the company on the 21st September...

The Company announces that it received notice today that Dr Jim Millen, the Company's CEO, has purchased a total of 200,000 ordinary shares in the Company at a price of 2.5p per share, being the most recent placing price, as announced on 21 September 2016, adjusted for the subsequent share consolidation. Following this transaction Dr Millen owns 200,000 ordinary shares in the Company representing approximately...

The Company is pleased to announce that all resolutions put to shareholders at the Annual General Meeting held today were passed. Please click here for further information....

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it is now entitled to a payment from Sareum Holdings plc (“Sareum”) for a three month modelling project conducted by the Company in 2010 in support of Sareum’s cancer drug joint research program with The Institute of Cancer Research (ICR) and Cancer Research Technology Limited (CRT), as originally announced...

Dispatch of Documentation: Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has published and posted to shareholders - its Annual Report for the financial year ended 30th June 2016 and - a circular in relation to a forthcoming Annual General Meeting As already announced on the 27 October 2016, the Company’s Annual General Meeting will be held at due to...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has been notified of Innovate UK’s intention to award the Company a grant for its proposed project “Decision Support Systems For Stratified Cancer Treatment”, as part of Innovate UK’s Biomedical Catalyst 2016 Feasibility Study Competition, co-funded by Scottish Enterprise and the Medical Research Council. Please click here for full...

Chairman’s Statement Summary of Results in the year ended 30 June 2016 • The turnover of the Company increased 26% to £297,120 (2015: £235,486) • The loss after net operating expenses (excluding share-based payments and operating exceptional costs) decreased 6% to £371,381 (2015: £395,329) • The operating loss increased 4% to £431,561 (2015: £414,755) • On 30 June 2016, the surplus of shareholders’ funds was £204,153 (2015: £325,617) This year, Physiomics...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce the appointment of Hybridan LLP as sole broker with effect from 28th December 2016. WH Ireland Limited will continue to act as the Company’s NOMAD. Please click here for full information....

The Company announces that it has completed a placing, conditional only on Admission, to raise £555,000.00 from the issue of 2,220,000,000 new ordinary shares of 0.004p each ("Ordinary Shares") at a price of 0.025p per share, through Hybridan LLP (the "Placing"). Application has been made for the new Ordinary Shares to be admitted to trading on AIM and dealing is expected to commence on 28th...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has today published and posted to shareholders a circular in relation to a forthcoming General Meeting, due to be held at the Company’s registered office, The Magdalen Centre, Oxford Science Park, Robert Robinson Avenue, Oxford, OX4 4GA at 10:00 a.m. on 7th September 2016. The directors will propose at...

Physiomics plc (AIM: PYC). Following the announcement on 31st March 2016 of its intention to acquire BioMoti Limited, the Company is pleased to announce that it has signed a Share Purchase Agreement with BioMoti. The acquisition remains conditional on the Company completing a successful placing to raise a minimum of £1m to develop the new joint company’s drug discovery and development pipeline. Please click here for...

Physiomics is pleased to announce that it has signed further extensions to a Virtual Tumour project with a major global pharmaceutical company, first announced on 1st March 2012.  The 6th extension will cover predicting optimal regimens for follow-up compounds and in vitro to in vivo translation, whereas the 7th extension will predict optimal regimens for a candidate in an additional cancer indication Read more...

The Company announces that Anthony Clayden, of Strategic Finance Director Limited, has been appointed Head of Finance to lead the financial management and provide company secretarial services with effect from 1 May 2016. This is not a board position, and Anthony is not being appointed a director or officer of Physiomics. At the same time the existing Financial Controller and Company Secretary, Liz King will...

Further to the announcement of 31 March 2016, the Company confirms that Dr James Simon Millen, aged 47 is to be appointed Chief Executive Officer of the Company with effect from today (18th April 2016). Dr James Millen, known also as Jim, has experience of drug development and of licensing deals in global pharma companies. The Company also confirms that Dr Mark Chadwick will step...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it is participating in the AACR Annual Meeting 2016, taking place at the Ernest N. Morial Convention Center, New Orleans, Louisiana on 16-20 April 2016. Dr Eric Fernandez will present on the application of the Virtual Tumour ("VT") platform to predict the emergence of resistance. Read more...

Further to the announcement of 22 December 2015, Physiomics is pleased to announce that it has signed a further contract with a speciality pharmaceutical company.  This extension to the work will be completed by the end of 2016. Read more...

Oxford, UK, 31 March 2016: The Board of Physiomics Plc (AIM: PYC), a UK-based systems biology company, today announces its financial results for the six months ended 31 December 2015. Physiomics Plc is a computational systems biology services company, applying simulations supporting pharmaceutical decision making throughout the entire drug discovery process, particularly for cancer therapies....

Physiomics plc is pleased to announce that it has signed a non-binding Heads of Terms agreement to acquire BioMoti Limited (“BioMoti”) (the “Proposed Acquisition”)....

Physiomics plc is pleased to announce that it has signed a new contract with another new speciality pharma customer, to perform PK/PD modelling analysis for a novel combination and translate the results into the clinic. This will be the Company's first project related to drugs treating pain    ...

The Company announces that it has completed a placing, conditional only on Admission, to raise £250,000 from the issue of 1,000,000,000 new ordinary shares of 0.004p each ("Ordinary Shares") at a price of 0.025p per share, through WH Ireland Limited (the "Placing"). Application has been made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on...

Chairman's Statement  Summary of Results in the year ended 30 June 2015 •    The turnover of the Company was £235,486 (2014: £267,903). •    The operating loss reduced to £414,755 (2014: £465,265). •    On 30 June 2015 the surplus of shareholders' funds was £325,617 (2014: £136,487). This year, Physiomics extended its product range and made a key commercial breakthrough, signing its first long term Virtual Tumour Clinical deal with a large pharmaceutical company. In summary...

Physiomics is pleased to provide an update on its strategic direction. For some time the Company has been pursuing M&A targets, in particular oncology therapeutics companies that could benefit from the application of Virtual Tumour and other PYC modelling tools. Physiomics has now identified a number of potential targets, including one in particular where the synergy with our modelling skills is strong....

Physiomics is pleased to announce that it has signed a new Virtual Tumour deal with a new pharmaceutical company, the 4th large pharma customer for this service...

Physiomics is pleased to announce that it has signed a further extension to a Virtual Tumour project with a major global pharmaceutical company, first announced on 1st March 2012. The extension will cover predicting optimal regimens for a candidate compound and should be completed by the end of 2015....

Physiomics will present a half-day workshop on “Applications of Physiomics’ Virtual Tumour to Immunotherapy and Translational Science”, ahead of the 2015 PAGE meeting. This workshop will review the preclinical Virtual Tumour model used to predict optimal doses and schedules of combination therapy. We will provide an overview regarding the recent extension of the current model to include immunotherapy and clinical translational. This will then be...

Physiomics plc is pleased to announce that it has signed its first contract for developing Virtual Tumour Clinical with a global pharmaceutical company. The client is Merck Serono, the biopharmaceutical division of Merck, Germany. Revenue from the contract will fall in the 2014/2015 and 2015/2016 financial years and is in the region of the total value of all of Physiomics 2013/2014 sales. As such it...

Chairman’s Statement   Summary of Results in the year ended 30 June 2014   The turnover of the Company increased by 12% to £267,903 (2013: £240,000). The operating loss reduced by 15% to £465,265 (2013: £548,342). On 30 June 2014 the surplus of shareholders’ funds was £136,487 (2013: £255,821). This year, Physiomics has made good progress advancing Virtual Tumour Clinical and has broadened its offering into the personalised medicine...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is delighted to announce that Merck & Co., a top 5 pharmaceutical company, has disclosed that it is a customer of Physiomics.   Merck & Co. published a paper in CPT: Pharmacometrics and Systems Biology (part of Nature Group) in which Virtual Tumour was specified as a technology which had helped their decision-making process...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a further extension to a Virtual Tumour project with a major global pharmaceutical company, first announced on 1st March 2012.  The extension will cover predicting optimal regimens for a further candidate compound and should be completed by the end of 2014...

Dr Eric Fernandez will present EasyAP at the Safety Pharmacology Society Meeting in Washington, DC, from the 19th to 22nd of October....

Physiomics is pleased to announce that it has now launched its predictive web-based platform for cardiac toxicity. EasyAP™ provides cardiac action potential time course simulations to facilitate the prediction of cardiac toxicity and compound selection. Read more....

Physiomics is pleased to announce that it has signed a new contract with a global pharmaceutical company. The project will involve adapting the existing Virtual Tumour to model immunomodulatory agents, currently a significant focus of cancer research. The initial phase of the project will be focused on making pre-clinical predictions. If successful, the project may be extended to also adapt Virtual Tumour Clinical to immune...

Physiomics is pleased to announce that it has signed a Heads of Terms agreement with Diatech Pharmacogenetics to negotiate a Collaboration Agreement. Under the terms of the anticipated Collaboration Agreement Physiomics and Diatech will develop an innovative in-silico platform to personalize cancer patient treatment. This anticipated new in-silico platform will combine pharmacological information related to cancer drugs with genomic and physiological information about the patient, to...

Physiomics is pleased to announce that it is presenting at the CASyM Academic / Industry interaction workshop taking place in Lyon (France) on April 10th 2014. Dr Hitesh Mistry will present on validation of the Virtual Tumour Clinical platform in melanoma to an audience that will comprise senior academics and large pharmaceutical company scientists. Read more....

Physiomics is pleased to announce that it is participating in the AACR Annual Meeting 2014, taking place at the San Diego Convention Center, San Diego, CA on 5-9 April 2014. Dr Eric Fernandez will present on the first validation of the Virtual Tumour Clinical platform. Read more....

The Board of Physiomics today announces its interim financial results for the six months ended 31 December 2013. Read more....

Physiomics plc is pleased to announce that it has signed a collaboration agreement with the University of Dundee. Physiomics part of the collaboration will be fully funded by the Northern Research Partnership (“NRP”) in the form of an “Early Career Researcher Engagement and Exchanges with Business & Industry” agreement. Read more....

Physiomics is pleased to announce that it has signed a substantial new contract with a major global pharmaceutical company. The programme of studies will begin immediately and take an estimated 9 months to reach a conclusion. Physiomics will determine the optimal dosing regimen of a new compound currently under development by this client. Read more....

Physiomics is pleased to announce that it has now launched its Drug Combinations and Regimens database. DrugCARD® collates curated publicly available pre-clinical and clinical drug regimen data into one easily searchable tool. It also contains further clinical data and analysis which is only available through the collaboration with Pharmacometrics. Read more....

Physiomics is pleased to announce that it has signed a collaboration agreement with the University of Oxford and the Oxford University Hospitals NHS trust to support the development of Physiomics’ flagship Virtual Tumour Clinical technology. Virtual Tumour Clinical is used to predict optimal clinical regimens for cancer trials. Physiomics has been seeking academic and industrial partners to help calibrate the model with key data obtained from...

Physiomics is pleased to announce that it is participating in the 2013 NCRI Cancer Conference, taking place at the BT Convention Centre, Liverpool, on 3-6 November 2013. Dr Eric Fernandez, Project Leader, will present details of the on-going development of the Virtual Tumour Clinical platform. The abstract ("Dosing and schedule optimization with Virtual Tumour Clinical ") No B60 will be presented in the "Diagnosis and...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a contract with a new speciality pharma customer, to investigate how one of its new candidate drugs shrinks tumours. Read more....

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a contract with its first large pharma customer to supply cardiac toxicity risk modelling services. Read more...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it is participating in the 2013 Safety Pharmacology Society's  annual Meeting (SPS), taking place at the Congress Centre de Doelen, Rotterdam, Netherlands, on 16-19 September 2013. Dr Hitesh Mistry will present the latest modelling advances of the cardiac toxicity predictive platform developed at Physiomics. Read more...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it won the second poster prize at the NC3Rs and Society of Biology Symposium held in London on 19 June 2013. The NC3Rs is the National Centre for the Replacement, Refinement & Reduction of Animals in Research. read more ...

Physiomics is pleased to announce that it has been awarded a GBP148,465 grant from the UK’s innovation agency, the Technology Strategy Board’s Biomedical Catalyst fund. The grant will provide additional support for the development of the Company’s flagship Virtual Tumour Clinical platform. Read more....

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it is participating in the PAGE Meeting 2013, taking place at the Glasgow Royal Concert Hall, Glasgow,  on 11-14 June 2013. Dr Eric Fernandez, Dr Frances Brightman, and Dr Christophe Chassagnole will present on an updated version of drugCARD, on our newly release cardiac toxicity predictive platform and on our...

The current Virtual Tumour platform is a mathematical model of a growing tumour which accurately predicts the outcome of xenograft experiments. The model can also be used as a start point to design first time in human clinical regimens. Physiomics is now developing Virtual Tumour Clinical, based on the same principles as the exiting platform but using human patient data to calibrate the model. Read more....

Physiomics plc is pleased to announce that it has signed a contract with a biotechnology company to apply its new Virtual Tumour Clinical platform to their lead compound. The biotechnology company will pay an up-front technology access fee now and ongoing service fees as the project progresses. This represents the first commercial deal for Physiomics’ flagship Virtual Tumour Clinical technology. The project will commence immediately. ...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it is participating in the AACR Annual Meeting 2013, taking place at the Walter E. Washington Convention Center, Washington, DC on 6-10 April 2013.  Dr Frances Brightman and Dr Eric Fernandez will present respectively on the application of the Virtual Tumour platform to radiotherapy prediction and on the latest...

Physiomics plc (AIM: PYC), the Oxford, UK-based systems biology company, is pleased to announce the launch of its new cardiac toxicity modelling service. This new model predicts the risk of a fatal heart arrhythmia known as Torsade de Pointes, using low cost and relatively easy to obtain lab-based data. From 1990 to 2010, a dozen compounds were withdrawn from the market because of association with...

The Physiomics method aims to reduce the number of candidates incorrectly rejected and also to reduce the number of compounds incorrectly advanced into costly clinical trials....

Discover the range of new services we now offer to drug clinical development companies....

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has entered into a £4 million Standby Equity Distribution Agreement ("SEDA") with YA Global Master SPV Ltd, an investment fund managed by Yorkville Advisors ("Yorkville") read more...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has been recognised by the French Ministry of Higher Education and Research as an eligible research organisation for French companies seeking to claim French Research and Development tax credits (“Agrément crédit d’impôt recherche") on their research projects (2012 to 2014). Read more...

Chairman’s Statement   Summary of Results in the year ended 30 June 2012   Fundraising in April 2012 generated cash of £555,000 before issue expenses. The turnover of the Company more than doubled to £135,306 (2011: £53,345). The operating loss reduced to £577,922 (2011: £693,795). On 30 June 2012 the surplus of shareholders’ funds was £734,570 (2011: £755,511). With a now fully validated Virtual Tumour technology, Physiomics has concentrated...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a new agreement with a top five pharma company.  Under the agreement, Physiomics will determine the optimal dosing and timing of a combination of two compounds currently under development by this new customer...

The Company announces that it has raised £555,000 from the issue of 370,000,000 new ordinary shares of 0.04p each ("Ordinary Shares") at a price of 0.15p per share, by way of a placing through WH Ireland Limited (the "Placing"). Application has been made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 2 May 2012...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it will be participating in the AACR Annual Meeting 2012, taking place at the McCormick Place West, Chicago, Illinois on March 31- April 4 2012.  Dr Frances Brightman, Senior Scientist at Physiomics, will present the application of the Virtual Tumour platform to three-dimensional cell cultures...

The Board of Physiomics Plc (AIM: PYC), a UK-based systems biology company, today announces the financial results for the six months ended 31 December 2011. Physiomics Plc is a computational systems biology services company, applying simulations supporting pharmaceutical decision making throughout the entire drug discovery process, particularly for cancer therapies. Read more...

Physiomics plc is pleased to announce that it has signed a new agreement with a major global pharmaceutical company. Under the agreement, Physiomics will determine the optimal dosing and timing of a new compound currently under development by this new client, in combination with irradiation therapy. Read more...

Physiomics plc (AIM: PYC), the Oxford, UK-based systems biology company, is pleased to announce its intention to increase the scope of its offering through the development of a new modelling service to predict the cardiac toxicity of drugs.  The Directors believe that this new service will be of particular interest to biotechnology companies looking to streamline their drug discovery programmes and improve the success rates...

  The below excerpt has been taken from InSphero’s latest newsletter, 'Upgrade Your Cell-Based Assays to 3D', discussing the collaboration between InSphero and Physiomics plc. Customer case study: 3D microtissue growth and drug response – virtual and in vitro models InSphero’s customer Physiomics plc develops computational systems-biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. The Oxford (UK)-based company has created detailed...

Physiomics (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it will be participating in the EORTC-NCI-AACR symposium on “Molecular Targets and Cancer Therapeutics”, taking place at the Moscone Center West, San Francisco, California on 12-16 November 2011. Dr Eric Fernandez, Project Leader at Physiomics, will present on a prototype version of an anti-cancer drug combination and regimen database. Dr...

Physiomics plc (AIM: PYC), the Oxford, UK based  systems biology company, is pleased to announce that it has signed a further agreement with Eli Lilly and Company ('Lilly'), the global pharmaceutical company, to perform two new projects for in silico simulations in the field of oncology.  The projects involve predicting the outcomes of proposed regimens for two Lilly candidate compounds in combination with other drugs. Read...

Physiomics (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has now executed its Joint Services Alliance with Jubilant Biosys Limited ("Jublilant"). Read more...

Physiomics Plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a collaborative agreement (“Agreement”) with a wholly owned subsidiary of ValiRx plc (AIM: VAL), ValiPharma Limited, a life science company with a focus on cancer diagnostics and therapeutics for personalized medicine, relating to the further development and accelerated progress of VAL201, ValiPharma’s anti-cancer compound. Read more...

Physiomics (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce the execution of a new collaboration agreement with Pharmacometrics Limited ("Pharmacometrics"), pursuant to which it is agreed that both parties will work together to develop an anti-cancer drug regimen and combination database. Read more...

The Company announces that it has raised £600,000 from the issue of 120,000,000 new ordinary shares of 0.04p each ("Ordinary Shares") at a price of 0.5p per share, by way of a placing through WH Ireland Limited (the "Placing"). Application has been made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 12 April 2011. Read...

Physiomics (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that positive results have been generated in a pre-clinical in-vivo study into breast cancer based on the Company’s “Virtual Tumour”  model predictions. The directors believe these results provide further validation as to the predictive capability of the Company’s technology. Read more...

Physiomics (AIM: PYC), the Oxford, UK, based systems biology company, is pleased to announce the appointment of Dr Mark Chadwick as Chief Executive Officer of the Company. As a Director of the Company he will join the main Board and the Remuneration Committee. Read more ...

Physiomics (AIM: PYC), the Oxford, UK based systems biology company,is pleased to announce that the Company together with Green Biologics Limited (GBL) and North Energy Associates Limited has been awarded a total grant for £268,000 from the Carbon Trust for a project to demonstrate an Advanced Fermentation Process for Butanol. Read more...

Physiomics (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has executed non legally binding head of terms of a joint services alliance with Jubilant Biosys Limited (“JBL”). ...

Physiomics have validated their Virtual Tumour model in single-blind experiments with a major pharma company. The model successfully predicted the outcome of two drug combination xenograft studies. The results are presented in an article for Innovations in Pharmaceutical Technology (June issue)....

Physiomics (AIM: PYC), the Oxford, UK based systems biology company, and Sareum Holdings plc (AIM: SAR) are pleased to announce that they have signed an agreement in which Physiomics provides in silico simulations to support Sareum’s cancer drug joint research program with The Institute of Cancer Research (ICR) and Cancer Research Technology Limited (CRT)....

The Company announces that it has completed a placing, through WH Ireland Limited, to raise £782,500 from the issue of 195,625,000 new ordinary shares of 0.04p each (“Ordinary Shares”) at a price of 0.4p per share (the “Placing”). Application has been made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 4 December 2009....

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to update the market on its trading performance for the financial year ended 30 June 2009. Revenues for the year were stronger than anticipated in a previous trading statement issued on 28 July 2008 and we were able to build on the improvement set out in the Interim statement issued in February...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce a successful evaluation, by the European Commission, of the results from the second year of the research program "TEMPO" . Following this successful review, the European Commission have agreed that the 3 year “TEMPO” project can continue into its final year as specified in the original grant proposal....

Physiomics (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a license agreement with Eli Lilly and Company ('Lilly') (NYSE: LLY), the global pharmaceutical company. Under the terms of the agreement, Physiomics will license to Lilly a customised version of its “ModelPlayer” for in silico simulations of unspecified anticancer drugs and Lilly will have the option...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a further agreement with Eli Lilly and Company ('Lilly') (NYSE: LLY), the global pharmaceutical company, to perform two new projects for in silico simulations in the field of oncology. Financial details of this agreement have not been disclosed. This follows the successful completion earlier this year...

Physiomics plc, the Oxford, UK based systems biology company, is pleased to announce that it will be participating in the 2008 AACR Annual Meeting, taking place in San Diego, on 12-16 April 2008. Dr Eric Fernandez will present a development update on the Company’s chronotherapy research program, as part of the EU funded TEMPO (Temporal Genomics for Tailored Chronotherapeutics) project. The abstract will be published...

ValiRx, the cancer therapeutics company, today announces that Phase 1 of its collaboration with Physiomics plc, the European systems biology simulation company, has been completed. Under the collaboration, originally announced in February 2007, Physiomics’ In Silico simulation technology has been successfully coupled with ValiRx’s GeneICE technology to generate a cancer cell death model – the Apoptosis Model....

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed an agreement with Eli Lilly and Company ('Lilly') (NYSE: LLY), the global pharmaceutical company, to provide in silico simulations of cancer cellular processes in support of Lilly's cancer drug discovery research....

ValiRx, the cancer therapeutics company, has signed a new agreement with Physiomics to use its in silico simulations of cellular processes to reduce the development time and costs associated in identifying new therapeutic compounds for the treatment of cancers. ...

Physiomics plc is pleased to announce that it has been selected to participate in the TEMPO (Temporal Genomics for Tailored Chemotherapeutics) Project as one of four Industry partners working closely with four distinguished European academic research groups...

Physiomics plc has developed a sophisticated addition to its core cell growth model showing why different cancer cells respond in different ways to an innovative new class of anti-cancer drugs. This was presented at the International Conference on Systems Biology meeting in Boston, USA, 19th-21st October 2005....

Physiomics and Bayer Technology Services GmbH (BTS) have signed an agreement under which BTS has appointed Physiomics as a distributor of its PK-Sim® pharmacokinetic modelling products and services for a renewable five-year period....

Physiomics plc has received formal notification from the UK Patent Office of registration to it in the UK of European Patent 0 937 286, which covers its SystemCell™ simulation technology. The corresponding US Patent 6,446,055 was granted on 3 September 2002 and assigned to Physiomics on 14 November 2002...

Physiomics plc and Cronos Therapeutics Ltd (now ValiRx plc) have entered into an alliance whereby Physiomics will use its novel in silico technology to select optimal targets for the highly-selective GeneICE technology from Cronos Therapeutics. The alliance will then codevelop the lead GeneICE constructs....

Bayer Technology Services, the engineering and applied science spin-off company of Bayer AG, and Physiomics plc announced today an agreement to cooperate in the field of clinical response prediction....